Prediction of symptomatic response to galantamine treatment by regional cerebral blood flow measurement in Alzheimer's disease patients.
Phase of Trial: Phase IV
Latest Information Update: 19 May 2016
Price : $35 *
At a glance
- Drugs Galantamine (Primary)
- Indications Alzheimer's disease
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 17 Jun 2015 Status changed from recruiting to completed.
- 09 Jul 2013 New trial record